PLCG2 and neoplasm: Multiple mechanisms responsible for the resistance of BTK inhibitors include mutations in BTK and downstream signaling molecules, such as PLCγ2, CARD11, and BCL10 leading to prolonged and BTK-independent NF-κB activation resulting in tumor cell growth.